Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX With or Without Erlotinib in Biliary Tract Carcinoma
NCT01149122Phase 3Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in biliary tract carcinoma (BTC), sponsored by Samsung Medical Center. Started Jan 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT01149122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01149122.